But over time, perhaps after the approval is where we may look to bring on sales teams to continue to educate the outdoor community that is our bet. We will have a medical team in place, whether it’s medical science layers on and continue to educate and also have a key account managers who are going to be the point of contact at these treatment centers where pz-cel will be placed. So that’s our model that we will have, which is to focus on key account managers and medical teams.
Unidentified Analyst: Got it. And then also going back to Krystal Biotech and now their launch of Vyjuvek for DEB comparing this to pz-cel, what are your overall thoughts and what takeaways do you see for pz-cel from this particular launch?
Madhav Vasanthavada: Our — I mean our takeaway is that this is great to see the uptake of these products, right? I mean, for far too long, these patients have had no really therapeutic options have been subjected to standard of care, the burden that they’ve had on treating their wounds has been just devastating for everyone so we are happy to see the awareness picking up. We are happy to see that patients are getting motivated. The insurance companies are beginning to cover these patients, and that was our major takeaway from our — from following what’s happening in this space is that payers are beginning to clear up the access. And I think what that means for pz-cel is a fantastic positioning because we are coming fast followers, which only helps a, number 1, helps raise the awareness for these patients and these physicians that there are therapeutic options coming into this space.
And number 2, for the paperwork and the access clearance and genetic copy of genetic testing so on and so forth, which is taking several weeks by the time that pz-cel comes to market, we will be in a better position. So these are really the positive takeaways for us, and we continue to learn as we approach our approval time lines.
Vishwas Seshadri: And also just not to forget differentiation, right, we’ve heard very clearly from the physicians that all these therapies are going to be needed by almost all the patients because the approach is very different. The value proposition is very different, and patients do have different types of wounds in their body. And for the large wounds where there’s a lot of pain and need instantaneous closure, the willingness to go for the big guns, if you may, like pz-cel is going to be there. So that’s what we’re learning and which is why a pent-up bolus of patients in centers of excellence is already kind of sufficient to take our launch infrastructure over and — which is why we’re not investing on a big sales force because we know these patients already exist.
Unidentified Analyst: Understood. Just one last question from us. You mentioned in the past the potential for pz-cel to be formulated [indiscernible] spray to have different skin graft sizes used for the patients. So when might you look into trying to get these additional indications or administration methods onto the label?
Vishwas Seshadri: Yes. I think from a perspective of life cycle management, this is really — we have to think hard whether it’s even pz-cel that comes at a spray. There’s probably going to be a whole new biological product. Clearly, there is some learning. I mean, we have been very disciplined in how to focus our finite resources, our job with the pz-cel launch is not yet done as much as we’re getting closer every day. So we are — we have these ideas. I think some of the common unmet need that we hear is can you make glove shaped grafts for mitten deformities because hand surgeries are a big part of these patients like and then can you do that? I think there’s a lot of that unmet need and ask from the patient community for these products.
We’re being careful that let’s get the pz-cel launched, let’s get the uptake, and we will be on our way for what improvements we can build. But clearly, that’s going to be not EB-101, EB-102. It’s going to be a different product that we are keeping our eyes and ears out to further understand the unmet need and design these products appropriately.
Operator: As we have no further questions in queue at this time. I would like to hand it back over to Mr. Seshadri for any closing comments.
Vishwas Seshadri: Thank you. In closing, I want to thank our shareholders and other stakeholders who have listened to this call, and we’ll talk to you again soon. Have a nice day.
Operator: Thank you. Ladies and gentlemen, this concludes today’s conference, and you may disconnect your lines at this time, and we thank you for your participation.
